Patient portrayal
ADVANCED CSCC1*
*FDA approved in advanced CSCC in 2018. Includes clinical trial
experience and post-marketing data.2

EVIDENCE THAT EMPOWERS CHANGE

LIBTAYO is the FIRST treatment indicated for patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.2

LIBTAYO was validated in the largest prospective clinical trial program for advanced CSCC1-12

Examine the data
1
Most-Prescribed IO by Oncologists in advanced CSCC13,14*
  • *Based on IQVIA medical claims data from October 2018 through December 2021. Claims calibrated with actual
    vials sold.13
11K
patients treated with LIBTAYO across all indications14†
  • Since its first approval in advanced CSCC in 2018.2

Examine the efficacy profile
of LIBTAYO

explore the data

Review case studies of patients
with advanced CSCC

See the results

Explore our video library featuring
medical experts

Watch now
  • CSCC=cutaneous squamous cell carcinoma; IO=immunotherapy.
LIBTAYO Surround® logo

Help eligible patients access LIBTAYO and navigate the health insurance process.

Learn About the LIBTAYO Surround Patient Support Program